Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.
LILLY CORPORATE CTR DROP CODE 1112 INDIANAPOLIS, IN 46285, USA Phone: 3172762000 Fax: 317-276-4878 Web: http://www.lilly.com
Industry:Large Cap Pharma Sector: Medical Fiscal Year End:December Last Reported Quarter:03/31/12 Next EPS Date:07/19/12
Capital Structure Solvency and Cash Flow
As of March 31, 2011, cash, cash equivalents, and short-term investments were $6.71 billion compared with $6.73 billion at December 31, 2010. Cash, cash equivalents, and short-term investments remained relatively flat due to an increase in cash flow from operations of $1.18 billion that was offset by dividend payment of $543.2 million, acquisitions of $417.6 million, and net purchases of property and equipment of $101.4 million.
Eli Lilly expects cash flows to be sufficient for funding capital expenditures of $800 - $900 million, acquisitions and dividend in 2011.
The company will be conducting an analyst day meeting on June 30, 2011, when an update on long-term guidance and the pipeline is expected.
Last edited Mon Jun 06, 2011 02:06 AM by SreelaBose (Zacks Investment Research)
6
Governance Social Responsibility and Employee Relations
Last edited Mon Jun 06, 2011 02:06 AM by SreelaBose (Zacks Investment Research)
Acquisitions Divestitures and Joint Ventures
Last edited Mon Jun 06, 2011 02:08 AM by SreelaBose (Zacks Investment Research)
Recent and Upcoming Events
Major Risks
Pipeline setbacks like the discontinuation of the development of semagacestat and teplizumab and the delay in Bydureon’s approval have increased concerns regarding the company’s long-term growth prospects.
Lilly is facing a major patent cliff during the 2010 – 2015 time period. About 74% of the company’s revenues will be exposed to generic competition in the next several years.
Last edited Mon Jun 06, 2011 02:09 AM by SreelaBose (Zacks Investment Research)
Created by: WikiMigrationBot.
Last Modification: Thursday 03 of June, 2010 08:01:01 CDT by WikiMigrationBot.
